株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:急性冠症候群 - 欧州主要5ヶ国での医薬品の予測と市場分析

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 312375
出版日 ページ情報 英文 277 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:急性冠症候群 - 欧州主要5ヶ国での医薬品の予測と市場分析 PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023
出版日: 2014年07月31日 ページ情報: 英文 277 Pages
概要

世界主要7ヶ国の急性冠症候群(ACS)治療薬の市場規模は、2013年現在で123億米ドルに達し、そのうち先発薬(ブランド薬)が50億ドル(全体の40%)、ジェネリック医薬品が73億ドル(同60%)を占めています。2023年には、全体的な市場規模は434億米ドル、そのうち先発薬は277億米ドル(64%)、ジェネリック医薬品は157億米ドル(36%)となる見通しです。世界各国で高齢者人口や生活慣習病(肥満など)の患者数が増加していることや、生物製剤が多用されていくことなどが、今後の市場動向を大きく左右する容易となります。他方、ACS治療薬の市場は既に飽和化・成熟化しており、治療薬の大半はすでにジェネリック医薬品が主体となっています。特に、スタチンはそのほとんどがジェネリック医薬品となり、安価で提供されています。一方で、ARB(アンジオテンシン受容体遮断薬)の場合は、相対的に高額な治療費のために、先発薬のシェアが高くなっています。欧州諸国の場合、ドイツが全体で第2位、英国が第3位の市場規模となっている一方、フランス・イタリア・スペインの市場規模は現在・将来とも相対的に小さな状態が続く見通しです。

当レポートでは、欧州主要5ヶ国(フランス・ドイツ・イタリア・スペイン・英国)における急性冠症候群(虚血症候群、ACS)の治療法に関する最新の研究・開発状況と、市場の将来展望とを分析し、疾患の概要や治療法、市場機会とアンメットニーズ、市場規模の動向(今後10年間分)、上市済み/治験中の主な治療薬のプロファイル(効能・安全性・市場競争力)、各国市場の現状と今後の方向性などの情報お届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態
    • 病因
    • 病態生理
    • 予後
    • 生活の質(QoL)
  • 症状

第4章 疾患の管理

  • 治療の概要
  • フランス
    • 診断
    • 臨床診療
  • ドイツ
  • イタリア
  • スペイン
  • 英国

第5章 競合企業の評価

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル
    • 繊維素溶解性(血栓溶解性)薬剤:組織プラスミノーゲン活性化因子(tPA)
    • Clopidogrel
    • Brilinta(チカグレロール)
    • Effient(プラスグレル)
    • Integrilin(エプチフィバチド)
    • Warfarin
    • Angiomax(ビバリルジン)
    • Arixtra(フォンダパリヌクス)およびヘパリン
    • スタチン:HMG-CoAレダクターゼ阻害剤
    • βアドレナリン受容体拮抗薬(ベータブロッカー)
    • レニンーアンギオテンシンーアルドステロン系(RAAS)阻害剤

第6章 アンメットニーズと市場機会

  • 概要
  • アテローム血栓症プラークへの直接的な治療法
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 繊維性心筋症および関連共存症の治療法
  • スタチン不耐性・難治性・不適合患者に対するLDL-C(低密度リポタンパク質コレステロール)降下用医薬品
  • NOAC(新型経口抗凝固剤)向けの解毒剤
  • 出血リスクを大幅に抑えた血液希釈剤

第7章 パイプライン評価

  • 概要
  • 治験の進行状況:相(フェーズ)別・進捗状況別
  • 治験中の有望な薬剤
    • Xarelto(リバロキサバン)
    • Cangrelor
    • Zontivity(ボラパキサル)
    • アリロクマブ(RGN727)
    • エボロクマブ(AMG 145)
    • ボコシズマブ(PF-04950615)
    • アナセトラピブ
    • エバセトラピブ
    • ダラプラディブ

第8章 市場の将来展望

  • 世界市場
    • 市場促進・阻害要因:世界全体の場合
  • フランス市場
    • 予測
    • 近年の主な動向
    • 市場促進・阻害要因
  • ドイツ市場
  • イタリア市場
  • スペイン市場
  • 英国市場

第9章 付録

図表一覧

目次

GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

France represents one of the smallest in terms of overall ACS drug sales. Next to the US market, Germany commands the largest global market share for the sale of ACS drugs. Italy's contribution to global sales in both 2013 and 2023 falls in the middle of the sales distribution for the 7MM covered in this forecast. Of the 7MMs that were forecast in this report, Spain's share of global sales is the smallest for both the 2013 base year and the final forecast year of 2023. Of the markets forecast here, the UK commands the third largest market share in both the 2013 base year and in 2023.

Scope

  • Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU ACS market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for ACS.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of drug performance.
  • Obtain sales forecast for drugs from 2013-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. France
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice
  • 4.3. Germany
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice
  • 4.4. Italy
    • 4.4.1. Diagnosis
    • 4.4.2. Clinical Practice
  • 4.5. Spain
    • 4.5.1. Diagnosis
    • 4.5.2. Clinical Practice
  • 4.6. UK
    • 4.6.1. Diagnosis
    • 4.6.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles
    • 5.3.1. Fibrinolytic (Thrombolytic) Drugs - Tissue Plasminogen Activator (tPA)
    • 5.3.2. Clopidogrel
    • 5.3.3. Brilinta (ticagrelor)
    • 5.3.4. Effient (prasugrel)
    • 5.3.5. Integrilin (eptifibatide)
    • 5.3.6. Warfarin
    • 5.3.7. Angiomax (bivalirudin)
    • 5.3.8. Arixtra (fondaparinux) and the Heparins
    • 5.3.9. Statins - HMG-CoA Reductase Inhibitors
    • 5.3.10. Beta-Adrenergic Receptor Antagonists (Beta Blockers)
    • 5.3.11. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Antidotes for New Oral Anticoagulants (NOACs)
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Blood-Thinning Agents with Significantly Reduced Bleeding Risks
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trials by Phase and Trial Status
  • 7.3. Promising Drugs in Clinical Development
    • 7.3.1. Xarelto (rivaroxaban)
    • 7.3.2. Cangrelor
    • 7.3.3. Zontivity (vorapaxar)
    • 7.3.4. Alirocumab (RGN727)
    • 7.3.5. Evolocumab (AMG 145)
    • 7.3.6. Bococizumab (PF-04950615)
    • 7.3.7. Anacetrapib
    • 7.3.8. Evacetrapib
    • 7.3.9. Darapladib

8. Market Outlook

  • 8.1. Global
    • 8.1.1. Drivers and Barriers - Global Issues
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. United Kingdom
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
    • 9.4.2. Diagnosed Acute Coronary Syndrome Patients
    • 9.4.3. Percent Drug-Treated Patients
    • 9.4.4. Drugs Included in Each Therapeutic Class
    • 9.4.5. Launch and Patent Expiry Dates
    • 9.4.6. General Pricing Assumptions
    • 9.4.7. Individual Drug Assumptions
    • 9.4.8. Generic Erosion
    • 9.4.9. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Reviewer
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Antiplatelet Agents that Inhibit Platelet Activation
  • Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
  • Table 3: Symptoms of Acute Coronary Syndrome
  • Table 4: Treatment Guidelines for Acute Coronary Syndrome in the 5EU
  • Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014
  • Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
  • Table 7: Commonly Used tPAs
  • Table 8: Product Profile - Tissue Plasminogen Activator (tPA)
  • Table 9: Fibrinolytics SWOT Analysis, 2014
  • Table 10: Product Profile - Plavix (clopidogrel)
  • Table 11: Clopidogrel SWOT Analysis, 2014
  • Table 12: Product Profile - Brilinta (ticagrelor)
  • Table 13: Brilinta (ticagrelor) SWOT Analysis, 2014
  • Table 14: Product Profile - Effient (prasugrel)
  • Table 15: Effient (prasugrel) SWOT Analysis, 2014
  • Table 16: Product Profile - Integrilin (eptifibatide)
  • Table 17: Integrilin (eptifibatide) SWOT Analysis, 2014
  • Table 18: Product Profile - Warfarin
  • Table 19: Warfarin SWOT Analysis, 2014
  • Table 20: Product Profile - Angiomax
  • Table 21: Angiomax (bivalirudin) SWOT Analysis, 2014
  • Table 22: Product Profile - Arixtra (fondaparinux)
  • Table 23: Arixtra (fondaparinux sodium) SWOT Analysis, 2014
  • Table 24: Product Profile - Lipitor
  • Table 25: Lipitor (atorvastatin) SWOT Analysis, 2014
  • Table 26: Product Profile - Crestor (rosuvastatin)
  • Table 27: Crestor (rosuvastatin) SWOT Analysis, 2014
  • Table 28: Product Profile - Zocor (simvastatin)
  • Table 29: Zocor (simvastatin) SWOT Analysis, 2014
  • Table 30: Commonly Used Beta Blockers
  • Table 31: Product Profile - Beta Blockers
  • Table 32: Beta Blockers SWOT Analysis, 2014
  • Table 33: Product Profile - Tekturna (aliskiren)
  • Table 34: Tekturna (aliskiren) SWOT Analysis, 2014
  • Table 35: Commonly Used ACE Inhibitors
  • Table 36: Product Profile - ACE Inhibitors
  • Table 37: ACE Inhibitor SWOT Analysis, 2014
  • Table 38: Commonly Used ARBs
  • Table 39: Product Profile - Angiotensin Receptor Blockers (ARBs)
  • Table 40: ARB SWOT Analysis, 2014
  • Table 41: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs)
  • Table 42: MRA SWOT Analysis, 2014
  • Table 43: Unmet Need and Opportunity in Acute Coronary Syndrome
  • Table 44: Acute Coronary Syndrome - Clinical Trials by Phase and Status, 2014
  • Table 45: Acute Coronary Syndrome - Late-Stage Pipeline, 2014
  • Table 46: Comparison of Therapeutic Classes in Development for ACS, 2014
  • Table 47: Product Profile - Xarelto (rivaroxaban)
  • Table 48: Xarelto (rivaroxaban) SWOT Analysis, 2014
  • Table 49: Product Profile - Cangrelor
  • Table 50: Cangrelor SWOT Analysis, 2014
  • Table 51: Product Profile - Zontivity (vorapaxar)
  • Table 52: Vorapaxar SWOT Analysis, 2014
  • Table 53: Product Profile - Alirocumab (RGN727)
  • Table 54: Alirocumab SWOT Analysis, 2014
  • Table 55: Product Profile - Evolocumab (AMG 145)
  • Table 56: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013 - Q1 2014
  • Table 57: Evolocumab SWOT Analysis, 2013
  • Table 58: Product Profile - Bococizumab (PF-04950615)
  • Table 59: Bococizumab (PF-04950615) SWOT Analysis, 2014
  • Table 60: Product Profile - Anacetrapib
  • Table 61: Anacetrapib SWOT Analysis, 2014
  • Table 62: Product Profile - Evacetrapib
  • Table 63: Evacetrapib SWOT Analysis, 2013
  • Table 64: Product Profile - Darapladib
  • Table 65: Darapladib SWOT Analysis, 2014
  • Table 66: Acute Coronary Syndrome Market - Drivers and Barriers, 2014
  • Table 67: Sales Forecasts ($m) for ACS in France, 2013-2023
  • Table 68: Key Events Impacting Sales for Acute Coronary Syndrome in France, 2014
  • Table 69: Acute Coronary Syndrome Market - Drivers and Barriers in France, 2014
  • Table 70: Sales Forecasts ($m) for ACS in Germany, 2013-2023
  • Table 71: Key Events Impacting Sales for Acute Coronary Syndrome in Germany, 2014
  • Table 72: Acute Coronary Syndrome Market - Drivers and Barriers in Germany, 2014
  • Table 73: Sales Forecasts ($m) for ACS in Italy, 2013-2023
  • Table 74: Key Events Impacting Sales for Acute Coronary Syndrome in Italy, 2014
  • Table 75: Acute Coronary Syndrome Market - Drivers and Barriers in Italy, 2014
  • Table 76: Sales Forecasts ($m) for ACS in Spain, 2013-2023
  • Table 77: Key Events Impacting Sales for Acute Coronary Syndrome in Spain, 2014
  • Table 78: Acute Coronary Syndrome Market - Drivers and Barriers in Spain, 2014
  • Table 79: Sales Forecasts ($m) for ACS in UK, 2013-2023
  • Table 80: Key Events Impacting Sales for Acute Coronary Syndrome in the UK, 2014
  • Table 81: Acute Coronary Syndrome Market - Drivers and Barriers in the UK, 2014
  • Table 82: Key Launch Dates
  • Table 83: Key Patent Expiries
  • Table 84: Price Sources and Calculations, by Country
  • Table 85: Physicians Surveyed, By Country

List of Figures

  • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
  • Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome
  • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
  • Figure 4: Electrocardiography in the Diagnosis of ACS
  • Figure 5: Acute Coronary Syndrome Therapeutics - Clinical Trials by Phase in the 7MM, 2014
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents for ACS, 2013-2023
  • Figure 7: Sales for Acute Coronary Syndrome in France by Drug Class, 2013-2023
  • Figure 8: Sales for Acute Coronary Syndrome in Germany by Drug Class, 2013-2023
  • Figure 9: Sales for Acute Coronary Syndrome in Italy by Drug Class, 2013-2023
  • Figure 10: Sales for Acute Coronary Syndrome in Spain by Drug Class, 2013-2023
  • Figure 11: Sales for Acute Coronary Syndrome in the UK by Drug Class, 2013-2023
Back to Top